Erasca, Inc. (ERAS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 13, 2026, details updated preliminary Phase 1 clinical data for Erasca, Inc.'s lead candidate, ERAS-0015, a pan-RAS molecular glue. The data pertains to the ongoing AURORAS-1 trial in patients with RAS-mutant solid tumors, with a data cutoff of May 25, 2026 for monotherapy results and July 6, 2026 for combination therapy results.
Key Clinical Metrics and Financial Status
Clinical Performance (Monotherapy):
- Indication: KRAS G12X Pancreatic Ductal Adenocarcinoma (PDAC) in second-line or greater (2L+) settings.
- Efficacy: 57% unconfirmed Overall Response Rate (uORR) at 8 weeks (N=7) at the Recommended Dose for Expansion (RDE) of 32 mg once daily (QD).
- Retention: At the 32 mg QD RDE, 6 of 7 patients remained on treatment. At the 24 mg QD RDE, 6 of 8 patients remained on treatment.
- Safety: No dose-limiting toxicities (DLTs) observed. Median relative dose intensity was 100% at both 24 mg and 32 mg QD. No discontinuations due to treatment-related adverse events (TRAEs).
Clinical Performance (Combination):
- Indication: Metastatic Colorectal Cancer in combination with Panitumumab.
- Status: No DLTs observed in the 16 mg cohort (4 evaluable patients). Dose escalation ongoing in the 24 mg cohort.
Financial Metrics: The filing does not provide specific revenue, profit, cash flow, debt, or liquidity figures. It notes that the company's ability to fund operations depends on its cash, cash equivalents, and marketable securities.
Material Changes and Development Plans
Building on an April 2026 announcement, this report provides data with additional patients and longer follow-up. Based on these results, Erasca announced accelerated development plans:
- NSCLC (2L+): Initiate potentially registration-enabling trial in the first half of 2027.
- PDAC (First Line): Initiate Phase 3 pivotal trial in 2027.
- NSCLC (RAS-mutant): Initiate Phase 3 pivotal trial in the second half of 2027 or first half of 2028.
Risks, Contingencies, and Management Commentary
Safety Contingency: One patient with heavily pretreated metastatic pancreatic adenocarcinoma experienced Grade 3 pneumonitis which progressed to Grade 5 (death) after the patient requested withdrawal of supportive care. The patient had pulmonary metastases and a history of lung cryoablation but no history of lung radiation.
Key Risks:
- Intellectual Property: Potential litigation from Revolution Medicines (RevMed) alleging patent infringement or trade secret misappropriation regarding ERAS-0015.
- Regulatory: FDA may require additional data before registrational trials; interim results are not indicative of final outcomes.
- Liquidity: Risk that capital resources may be consumed sooner than expected.
- Development: Risks associated with the novel RAS/MAPK pathway approach and dependence on third-party manufacturers.
Investor Verification Checklist
- Verify the confirmation status of the 57% unconfirmed response rate (uORR) in the PDAC cohort.
- Review the specific details of the intellectual property dispute with Revolution Medicines in prior filings (10-K).
- Assess the company's current cash runway against the accelerated timeline for Phase 3 trials starting in 2027.
- Monitor the safety profile of the combination therapy with Panitumumab as dose escalation continues.
- Confirm the FDA's feedback on the proposed registration-enabling trial designs for NSCLC and PDAC.